Supplements and Featured Publications
- Managed Care Considerations for a First-in-Class M1/M4 Muscarinic Agonist for the Treatment of Adults With Schizophrenia
Managed Care Considerations for a First-in-Class M1/M4 Muscarinic Agonist for the Treatment of Adults With Schizophrenia
This clinical brief is supported by Bristol Myers Squibb and is intended for payers, formulary committees, or other similar individuals or entities with knowledge and expertise in the area of health care economic analysis carrying out responsibilities for the selection for the selection of drugs for coverage, reimbursement, or other population-based health care management.
This article describes the efficacy and safety of a first-in-class treatment for adults with schizophrenia.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.